HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Short Interest Down 12.6% in January

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) saw a significant drop in short interest in the month of January. As of January 15th, there was short interest totaling 332,424 shares, a drop of 12.6% from the December 31st total of 380,391 shares. Based on an average daily volume of 74,544 shares, the days-to-cover ratio is currently 4.5 days. Approximately 0.2% of the shares of the company are sold short. Approximately 0.2% of the shares of the company are sold short. Based on an average daily volume of 74,544 shares, the days-to-cover ratio is currently 4.5 days.

Hedge Funds Weigh In On HUTCHMED

Several large investors have recently bought and sold shares of HCM. Blue Trust Inc. raised its stake in HUTCHMED by 131.5% during the fourth quarter. Blue Trust Inc. now owns 7,708 shares of the company’s stock worth $103,000 after buying an additional 4,378 shares during the last quarter. Vanguard Personalized Indexing Management LLC boosted its position in shares of HUTCHMED by 23.2% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 15,490 shares of the company’s stock valued at $233,000 after purchasing an additional 2,916 shares in the last quarter. Ameriprise Financial Inc. grew its stake in HUTCHMED by 4.7% during the second quarter. Ameriprise Financial Inc. now owns 15,519 shares of the company’s stock worth $234,000 after purchasing an additional 698 shares during the period. Bank of America Corp DE increased its holdings in HUTCHMED by 17.3% in the second quarter. Bank of America Corp DE now owns 20,582 shares of the company’s stock worth $310,000 after purchasing an additional 3,035 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its stake in HUTCHMED by 34.2% in the third quarter. Dimensional Fund Advisors LP now owns 21,721 shares of the company’s stock valued at $342,000 after buying an additional 5,538 shares during the period. 8.82% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

HCM has been the topic of a number of analyst reports. Jefferies Financial Group raised HUTCHMED to a “strong-buy” rating in a research report on Monday, January 19th. Weiss Ratings reissued a “hold (c)” rating on shares of HUTCHMED in a report on Thursday, January 22nd. Finally, Wall Street Zen upgraded HUTCHMED from a “hold” rating to a “buy” rating in a research report on Sunday, November 16th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $20.88.

HUTCHMED Trading Down 2.9%

HUTCHMED stock opened at $14.56 on Tuesday. The stock has a fifty day moving average of $14.30 and a 200-day moving average of $15.36. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.65 and a quick ratio of 4.51. HUTCHMED has a 52 week low of $11.51 and a 52 week high of $19.50.

About HUTCHMED

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.